Ohio State University Comprehensive Cancer Center: Leukemia trials

The registry lists 12 Leukemia studies with Ohio State University Comprehensive Cancer Center as lead sponsor. 1 are open to participants now and 2 have results posted.

Phase 1 4Phase 2 5No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Hairy Cell Leukemia Patient Data RegistryRecruitingNCT02560883
• Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With AlemtuzumabCompletedNCT04312841Phase 2Results posted
• Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell TransplantationCompletedNCT01491958Phase 2Results posted
• Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia PatientsCompletedNCT04597086Not applicable
• Aromatherapy and Essential Oils in Improving Insomnia and Other Symptoms in Patients With Newly Diagnosed Acute Leukemia Undergoing ChemotherapyCompletedNCT02445378Not applicable
• Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)CompletedNCT01212380Phase 1
• Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaStatus unknownNCT01005758Phase 2
• Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT00624936Phase 1
• Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic LeukemiaCompletedNCT00201721Phase 2
• Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00143065Phase 2
• Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT00124644Phase 1
• FR901228 in Treating Patients With Hematologic CancerCompletedNCT00024180Phase 1